ID   SJNB-10
AC   CVCL_1441
SY   SJ-NB-10; SJ-NB10; SJNB10; NB10; NB10-DH; NB 90-9; NB90-9
DR   BTO; BTO:0006052
DR   CLO; CLO_0037083
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 946
DR   cancercelllines; CVCL_1441
DR   Cell_Model_Passport; SIDM00259
DR   ChEMBL-Cells; CHEMBL3308172
DR   ChEMBL-Targets; CHEMBL2366243
DR   Cosmic; 688069
DR   Cosmic; 949171
DR   Cosmic; 1109121
DR   Cosmic; 1518076
DR   Cosmic; 1526644
DR   Cosmic; 1543770
DR   Cosmic; 2239458
DR   Cosmic-CLP; 949171
DR   DepMap; ACH-002278
DR   EGA; EGAS00001000978
DR   GDSC; 949171
DR   GEO; GSM692861
DR   GEO; GSM1670146
DR   IARC_TP53; 27181
DR   LINCS_LDP; LCL-1989
DR   PharmacoDB; NB10_985_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1441
DR   Wikidata; Q54953554
RX   DOI=10.1007/0-306-46872-7_2;
RX   PubMed=8490657;
RX   PubMed=8516298;
RX   PubMed=10935473;
RX   PubMed=20164919;
RX   PubMed=20655465;
RX   PubMed=22213050;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 7765; NF1; Unexplicit; Partial deletion; Zygosity=Homozygous (PubMed=20655465).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.93%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=1.43%; European, North=66.44%; European, South=31.2% (PubMed=30894373).
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 11,12
ST   D5S818: 11
ST   D7S820: 11,12
ST   TH01: 6
ST   TPOX: 8,10
ST   vWA: 16,17
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   2Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 34
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
//
RX   PubMed=8490657; DOI=10.1038/ng0193-62;
RA   The I., Murthy A.E., Hannigan G.E., Jacoby L.B., Menon A.G.,
RA   Gusella J.F., Bernards A.;
RT   "Neurofibromatosis type 1 gene mutations in neuroblastoma.";
RL   Nat. Genet. 3:62-66(1993).
//
RX   PubMed=8516298; DOI=10.1073/pnas.90.12.5539;
RA   Johnson M.R., Look A.T., DeClue J.E., Valentine M.B., Lowy D.R.;
RT   "Inactivation of the NF1 gene in human melanoma and neuroblastoma cell
RT   lines without impaired regulation of GTP.Ras.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:5539-5543(1993).
//
RX   PubMed=10935473; DOI=10.1038/sj.neo.7900010;
RA   Kong X.-T., Valentine V.A., Rowe S.T., Valentine M.B., Ragsdale S.T.,
RA   Jones B.G., Wilkinson D.A., Brodeur G.M., Cohn S.L., Look A.T.;
RT   "Lack of homozygously inactivated p73 in single-copy MYCN primary
RT   neuroblastomas and neuroblastoma cell lines.";
RL   Neoplasia 1:80-89(1999).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20655465; DOI=10.1016/j.cell.2010.06.004;
RA   Holzel M., Huang S.-D., Koster J., Ora I., Lakeman A., Caron H.N.,
RA   Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C.,
RA   Messiaen L.M., Versteeg R., Bernards R.;
RT   "NF1 is a tumor suppressor in neuroblastoma that determines retinoic
RT   acid response and disease outcome.";
RL   Cell 142:218-229(2010).
//
RX   PubMed=22213050; DOI=10.1002/ijc.27415;
RA   Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J.,
RA   Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.;
RT   "PEA15 impairs cell migration and correlates with clinical features
RT   predicting good prognosis in neuroblastoma.";
RL   Int. J. Cancer 131:1556-1568(2012).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//